The value of cervical microenvironmental next-generation sequencing macrogenomic analysis in the diagnosis, treatment and progression prediction of cervical lesions

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300068479

Enrollment

Unknown

Registered

2023-02-21

Start date

2023-02-20

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer and cervical intraepithelial neoplasia

Interventions

Case series:not applicable

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years, pre-menopausal. 2. those with suspected cervicitis, cervical erosion, cervical polyps, cervical intraepithelial neoplasia, cervical cancer and other cervical diseases or health check-ups 3. Those who need to undergo cervical cytology and HPV screening for routine medical treatment. 4. Those who obtained informed consent.

Exclusion criteria

Exclusion criteria: 1. Insufficient sample collection, confused records or have been contaminated beyond the user. 2. A previous history of neoplasm other than cervical cancer 3. Those who have received immunosuppressive therapy or anti-infective treatment within the last two weeks 4. In the state of pregnancy or within 8 weeks after delivery 5. History of sub/total hysterectomy or treatment of cervical injury prior to enrollment.

Design outcomes

Primary

Measure	Time frame
Cervical cytology;Human papillomavirus infection;Cervical histopathology;Metagenomic sequencing data;	—

Countries

China

Contacts

Public ContactXu Xiaogang

Huashan Hospital, Fudan University/Institute of Antibiotics

xuxiaogang@fudan.edu.cn+86 138 1750 7007

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026